Aisling Capital Team

Aisling Capital is led by a group of investment professionals with diverse backgrounds in
industry, science and finance.

The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.

  • Steven Elms

    Managing Partner

    Steven Elms

    Mr. Elms joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, he was a Principal in the Life Sciences Investment Banking Group of Chase H&Q (formerly Hambrecht & Quist, “H&Q”).  During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.

    Mr. Elms currently serves as a director of ADMA Biologics, Ajax Health II and Zosano Pharma, and as a board observer of Marker Therapeutics and Verona Pharma. His prior board service includes Adams Respiratory Therapeutics, Advion BioSciences, Ambit Biosciences (acquired by Daiichi-Sankyo), Archimica Cooperatief (acquired by Euticals), Avera Pharmaceuticals, Bioenvision (acquired by Genzyme), CeNeRx BioPharma, Cidara Therapeutics, EarLens, LENSAR, Loxo Oncology (acquired by Eli Lilly), MAP Pharmaceuticals, NextWave Pharmaceuticals (acquired by Pfizer), Novazyme Pharmaceuticals (acquired by Genzyme), Oculex Pharmaceuticals (acquired by Allergan), Pernix Therapeutics, Scerene Healthcare and TRIA Beauty. He also serves on the INVO Board at Northwestern University.

    Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.

  • Andrew Schiff, MD

    Managing Partner

    Andrew Schiff, MD

    Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.

    Dr. Schiff currently serves as a director of Aclaris Therapeutics and ARMGO Pharma, and as a board observer of Harmony Biosciences. His prior board service includes Adams Respiratory Therapeutics, Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision (acquired by Genzyme), CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Miramar Labs (acquired by Sientra), Myogen, PowerVision (acquired by Alcon), Quintiles, SkinMedica (acquired by Allergan), Sirion Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by Nabriva) and ZELTIQ Aesthetics (acquired by Allergan).  He is a longtime supporter and board member of the Visiting Nurse Service of New York.

    Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.

  • Eric Aguiar, MD


    Eric Aguiar, MD

    Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.

    Dr. Aguiar currently serves as a director of Biohaven Pharmaceutical Holding Company, BridgeBio Pharma, Eidos Therapeutics and Invitae, and as a board observer of PellePharm. His prior board service includes Amarin, CardioKine, Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals. Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations.

    Dr. Aguiar received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

  • Aftab Kherani, MD


    Aftab Kherani, MD

    Dr. Kherani joined Aisling in 2008 and serves as a Partner. Prior to Aisling, Dr. Kherani was an Engagement Manager for two years at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.

    Dr. Kherani currently serves as Interim Chief Medical Officer of Ajax Health II, as a director of TransEnterix and as a board observer of ARMGO Pharma. His prior board service includes Ajax Health (acquired by Medtronic), Arcus Biosciences, EarLens, Loxo Oncology (acquired by Eli Lilly), Spirox (acquired by Entellus), Syros Pharmaceuticals and T2 Biosystems.

    Dr. Kherani received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient, and his B.S. in Biology and A.B. in Economics from Duke University, awarded magna cum laude and graduating Phi Beta Kappa.

  • Stacey D. Seltzer


    Stacey D. Seltzer

    Ms. Seltzer joined Aisling in 2008 and serves as a Partner. Prior to Aisling, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving at U.S. Schering-Plough as Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.

    Ms. Seltzer currently serves as a director of Aimmune Therapeutics and Promentis Pharmaceuticals, and as a board observer of Prolacta Bioscience. Her prior board service includes Agile Therapeutics, AVROBIO, Durata Therapeutics (acquired by Actavis), Miramar Labs (acquired by Sientra) and ZELTIQ Aesthetics (acquired by Allergan). She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant). Ms. Seltzer serves on the Life Science Council for Springboard Enterprises and the Investment Advisory Board of the Blavatnik Fund for Innovation at Yale.

    Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar, and her M.S. and B.S. in Molecular Biophysics and Biochemistry from Yale University, awarded cum laude.

  • Hallee Foster


    Hallee Foster

    Ms. Foster joined Aisling in 2017 and serves as an Analyst. Prior to Aisling, Ms. Foster was an Associate Consultant at Bain & Company in New York with a focus in healthcare.

    Ms. Foster received her B.S. in Neuroscience from Brown University, awarded magna cum laude, and graduating Phi Beta Kappa.

  • Robert Wenzel

    Chief Financial Officer

    Robert Wenzel

    Mr. Wenzel joined Aisling in 2008 and serves as the Chief Financial Officer and Chief Compliance Officer.  Prior to Aisling, he was a Vice President at Lazard Alternative Investments (“Lazard”) where he supervised the financial reporting of several domestic and offshore private equity funds. Prior to Lazard, Mr. Wenzel began his career at Eisner & Lubin, LLP, a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele, attaining the role of Senior Accountant.

    Mr. Wenzel received his B.B.A. in Accounting from Baruch College and holds his Certified Public Accountant license in the state of New York. He is also a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.

  • Hannah Wieder


    Hannah Wieder

    Ms. Wieder joined Aisling in 2017 and serves as the Controller. Prior to Aisling, she was an audit manager in the wealth & asset management practice at Ernst & Young, where she focused on private equity. Ms. Wieder also spent six years in the financial services group at CohnReznick, a midsize public accounting firm, where she attained the role of Audit Manager and directed the annual audits of various clients within the financial services industry including private equity funds, fund of funds and management companies.

    Ms. Wieder received her M.S. in accountancy from the Zicklin School of Business at Baruch College and her B.S. in business management and finance from Brooklyn College, awarded magna cum laude. She holds her Certified Public Accountant license in the state of New York and is a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.

  • Jan Hoerrner

    Director of Investor Relations and Marketing

    Jan Hoerrner

    Ms. Hoerrner joined Aisling in 2000 and serves as the Director of Investor Relations and Marketing.  In this role, Ms. Hoerrner manages relationships with over 90 limited partners and is a key contributor in Aisling’s fundraising and marketing efforts.  Prior to Aisling, Ms. Hoerrner was with H&Q, a leading underwriter and strategic advisor to the biotechnology industry.  During her five years at H&Q, Ms. Hoerrner was responsible for coordinating their healthcare conferences and also served as Administrative Manager for the New York office.

    Ms. Hoerrner received her B.S. in Business Administration from Bryant University.

  • Josh Bilenker, MD

    Operating Partner

    Josh Bilenker, MD

    Dr. Bilenker joined Aisling in 2006 and has served as an Operating Partner of Aisling since 2014. He was a full-time employee of Aisling from 2006 and 2014 and served as a Partner from 2012 to 2014. From 2013 until the acquisition of Loxo Oncology (an Aisling portfolio company) by Eli Lilly, Dr. Bilenker served as Loxo’s President and Chief Executive Officer. Prior to Aisling, Dr. Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.

    Dr. Bilenker currently serves as a director of Gossamer Bio. His prior board service includes Aragon Pharmaceuticals, LENSAR, Loxo Oncology (acquired by Eli Lilly), Roka Bioscience, T2 Biosystems, and ViewRay. He is also a Board Member of the NCCN Foundation and of BioEnterprise.

    Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.

  • Scott Braunstein, MD

    Operating Partner

    Scott Braunstein, MD

    Dr. Braunstein has served as an Operating Partner of Aisling since 2015. He recently served as Chief Operating Officer at Pacira Pharmaceuticals, Inc. During his tenure at Pacira, his role included being the SVP of Strategy, Chief Strategy Officer, and Chief Operating Officer. From 2002 to 2014, Dr. Braunstein worked as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He completed his training at The New York Hospital-Cornell Medical Center.

    Dr. Braunstein currently serves as director of ArTara Therapeutics, Constellation Pharmaceuticals, Esperion Therapeutics, Marinus Pharma, SiteOne Therapeutics, Trevena and Ziopharm Oncology.

    Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and his B.S. from Cornell University.

  • Dennis Purcell

    Founder and Senior Advisor

    Dennis Purcell

    Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

    Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

    Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.

    Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.